
Opinion|Videos|June 4, 2017
Results of the LATITUDE Trial in High-Risk Metastatic Hormone-Naive Prostate Cancer
Author(s)Kim N. Chi, MD
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Advertisement
Kim Chi, MD, professor, University of British Columbia, discusses results of the phase III LATITUDE trial of androgen deprivation therapy with abiraterone acetate plus prednisone (Deltasone) or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Most Patients Prefer SC Over IV Pembrolizumab, Phase 2 Data Show
2
Gedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer
3
First Patients Dosed With DOC1021 in Phase 1/2 Melanoma Trial
4
Tucatinib Maintenance Extends PFS Across HER2+ Breast Cancer Subgroups
5






































